A Phase 3 interventional study of clopidogrel (SR25990C) and placebo in Atrial Fibrillation and Vascular Risk, sponsored by Sanofi. Completed at 30 sites in 30 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2015-06-15.
Sponsored by Sanofi · Phase 3, Interventional, and Prevention
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 23 studies in Atrial Fibrillation by Sanofi — none open to participants now, none under way, none of them phase 3. Atrial Fibrillation · Sanofi.
Among the 23 studies in Atrial Fibrillation by Sanofi, this one is the 2nd largest by enrollment of the 20 interventional ones that give a count, is one of 4 that started in 2003, is one of 11 in phase 3, and was the 6th registered.
4,011 studies on the registry are indexed under Atrial Fibrillation; 961 are open to participants now.
Browse Atrial Fibrillation studies →None of the 23 studies in Atrial Fibrillation by Sanofi is open now. The open studies under Atrial Fibrillation, anywhere →
Of the 611 Atrial Fibrillation studies recruiting now, 407 (67%) set no upper age limit and 43 (7%) stop at 75 or younger; 21 take children under 18; 43 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
23 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 2 3 · Phase 3 12 · Phase 4 6
First in 2001; this study’s year is marked. 4 started in 2003.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 7,554 is above the median of 150 across 2,477 interventional studies indexed under Atrial Fibrillation.
Median enrollment 560 across the 20 interventional studies, 3,491 across the 3 observational. Of the 23 that completed or were terminated, 7 (30%) have results posted.
This tab as a report to print or save as PDF → With an account.
Sanofi is the lead sponsor of 1,558 studies on the registry; 89 are open to participants now.
Of its 205 completed or terminated interventional studies of FDA-regulated products, 123 (60%) have results posted.
None of the studies under way reaches primary completion within a year.
Among the 23 studies in Atrial Fibrillation by Sanofi, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to determine if the combination of clopidogrel 75mg once daily (od) plus aspirin 100mg daily (recommended dose) is better than aspirin alone (100mg daily recommended dose) for preventing vascular events such as stroke and heart attack during approximately three years of follow-up in patients with atrial fibrillation associated with at least one major risk factor of vascular event such as elderly, blood pressure increase, history of stroke or transient ischemic attack or left ventricular dysfunction etc. The study will also accept patients with atrial fibrillation and unwilling to take oral anticoagulant therapy.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
To be eligible for ACTIVE A patients must have in same time the three following conditions :
Evidence of high risk of vascular events : at least one of the following risk criteria must be present :
Exclusion Criteria:
Patients will be excluded from ACTIVE if any of the following are present :
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
TIA (transient ischaemic attack)
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
LVEF (left ventricular ejection fraction)
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Platelets
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clopidogrel 75 mg once daily (od) plus acetylsalicyclic acid (ASA) 75 to 100 mg od recommended (dose at the investigators' discretion)
Drug: clopidogrel (SR25990C)
Matching placebo of clopidogrel 75 mg od plus acetylsalicyclic acid (ASA) 75 to 100 mg od recommended (dose at the investigators' discretion)
Drug: placebo
oral administration (tablets)
Also known as: Plavix®
oral administration (tablets)
First Occurence of Any Component of the Composite of Stroke, Non-Central Nervous System (Non-CNS) Systemic Embolism, Myocardial Infarction or Vascular Death as Per Adjudication
The primary event is the first occurence of any adjudicated component of the following cluster over the duration of follow-up : * stroke (nonfatal or fatal) * myocardial infarction (nonfatal or fatal) * non-CNS systemic embolism * vascular death The primary efficacy analysis is performed on the time from randomization to this primary event. Numbers of patients with the composite event over the duration of the follow-up are presented by arm group.
Time frame: expected median follow-up of approximately 3 years
Occurrence of Stroke
The event is the occurence of stroke (nonfatal or fatal, ischemic, hemorrhagic or of uncertain type) after validation of the Event Adjudication Committee . The analysis is performed on the time from randomization to the occurrence of this event. Numbers of patients with the event over the duration of the follow-up are presented by arm group.
Time frame: expected median follow-up of approximately 3 years
Death From Any Cause (Cardiovascular and Noncardiovascular)
The considered event is death from any cause. The analysis is performed on the time from randomization to this event. Numbers of patients with the event over the duration of the follow-up are presented by arm group.
Time frame: expected median follow-up of approximately 3 years
Adjudicated Major Bleedings
The number of participants with at least one major bleeding, validated by the Event Adjudication Committee are counted over the duration of the follow-up (including after permanent discontinuation of the study drug).
Time frame: expected median follow-up of approximately 3 years
Patients were enrolled from June 2003 until May 2006. The study was conducted at 580 centers in 33 countries. The planned final follow-up visit date ensuring a median follow-up of three years was November 2008. The follow-up of the study was actually completed on March 2009 corresponding to an actual median follow-up of 3.5 years.
| Milestone | Clopidogrel + ASA | Placebo + ASA |
|---|---|---|
| Started | 3772 | 3782 |
| Completed | 2442 | 2528 |
| Not completed | 1330 | 1254 |
| Withdrew: Not treated | 7 | 8 |
| Withdrew: Significant thrombocytopenia | 9 | 8 |
| Withdrew: Severe allergic reaction | 8 | 1 |
| Withdrew: Serious haemorrhagic adverse event | 74 | 30 |
| Withdrew: Other serious adverse event | 86 | 97 |
| Withdrew: Qualifying condition not present | 20 | 23 |
| Withdrew: Contraindication to oral anticoagulant | 4 | 8 |
| Withdrew: Withdrawal by subject | 504 | 466 |
| Withdrew: Lost to follow-up | 4 | 7 |
| Withdrew: Minor bleeding | 99 | 37 |
| Withdrew: Non-compliance | 41 | 46 |
| Withdrew: Other non serious adverse event | 112 | 108 |
| Withdrew: Other contraindicated medication | 1 | 0 |
| Withdrew: Patient not wish to continue after may08 | 3 | 4 |
| Withdrew: Physician withdrew consent | 59 | 60 |
| Withdrew: Open label clopidogrel required | 31 | 42 |
| Withdrew: Angiotensin ii receptor blocker required | 1 | 0 |
| Withdrew: Oral anticoagulant required | 159 | 157 |
| Withdrew: Study drug intolerance | 5 | 0 |
| Withdrew: Surgery/ procedure | 9 | 9 |
| Withdrew: Event related to cardiac condition | 12 | 21 |
| Withdrew: Thromboembolic/outcome event | 82 | 122 |
The primary event is the first occurence of any adjudicated component of the following cluster over the duration of follow-up : * stroke (nonfatal or fatal) * myocardial infarction (nonfatal or fatal) * non-CNS systemic embolism * vascular death The primary efficacy analysis is performed on the time from randomization to this primary event. Numbers of patients with the composite event over the duration of the follow-up are presented by arm group.
| participants | Clopidogrel + ASA | Placebo + ASA |
|---|---|---|
| All components | 832 | 924 |
| - Myocardial Infarction (fatal or not) | 84 | 105 |
| - Stroke (fatal or not) | 285 | 391 |
| - Non-CNS systemic embolism | 50 | 48 |
| - Vascular death | 413 | 380 |
The event is the occurence of stroke (nonfatal or fatal, ischemic, hemorrhagic or of uncertain type) after validation of the Event Adjudication Committee . The analysis is performed on the time from randomization to the occurrence of this event. Numbers of patients with the event over the duration of the follow-up are presented by arm group.
| participants | Clopidogrel + ASA | Placebo + ASA |
|---|---|---|
| Occurrence of Stroke | 296 | 408 |
The considered event is death from any cause. The analysis is performed on the time from randomization to this event. Numbers of patients with the event over the duration of the follow-up are presented by arm group.
| participants | Clopidogrel + ASA | Placebo + ASA |
|---|---|---|
| Death From Any Cause (Cardiovascular and Noncardiovascular) | 825 | 841 |
The number of participants with at least one major bleeding, validated by the Event Adjudication Committee are counted over the duration of the follow-up (including after permanent discontinuation of the study drug).
| participants | Clopidogrel + ASA | Placebo + ASA |
|---|---|---|
| Adjudicated Major Bleedings | 251 | 162 |
Collected over From randomization through 28 days after the end of study drug treatment or the final follow-up visit. In both treatment groups, median duration of exposure was approximately 36 months, with a maximum of 62 months.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Clopidogrel + ASA | — | 1,154/3,772 (30.6%) | 2,542/3,772 (67.4%) |
| Placebo + ASA | — | 1,069/3,782 (28.3%) | 2,502/3,782 (66.2%) |
| Event | Clopidogrel + ASA | Placebo + ASA |
|---|---|---|
| PneumoniaInfections and infestations | 139/3772 | 128/3782 |
| OsteoarthritisMusculoskeletal and connective tissue disorders | 28/3772 | 36/3782 |
| Upper gastrointestinal haemorrhageGastrointestinal disorders | 28/3772 | 7/3782 |
| Chronic obstructive pulmonary diseaseRespiratory, thoracic and mediastinal disorders | 28/3772 | 27/3782 |
| Urinary tract infectionInfections and infestations | 23/3772 | 28/3782 |
| SepsisInfections and infestations | 27/3772 | 19/3782 |
| Gastrointestinal haemorrhageGastrointestinal disorders | 26/3772 | 9/3782 |
| FallInjury, poisoning and procedural complications | 24/3772 | 19/3782 |
| Prostate cancerNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 24/3772 | 16/3782 |
| Renal failure acuteRenal and urinary disorders | 22/3772 | 23/3782 |
| Event | Clopidogrel + ASA | Placebo + ASA |
|---|---|---|
| Any Infections and infestationsInfections and infestations | 994/3772 | 961/3782 |
| Any Gastrointestinal disordersGastrointestinal disorders | 806/3772 | 763/3782 |
| Any Nervous system disordersNervous system disorders | 661/3772 | 682/3782 |
| Any Musculoskeletal and connective tissue disordersMusculoskeletal and connective tissue disorders | 532/3772 | 623/3782 |
| Any General disorders and administration site conditionsGeneral disorders | 582/3772 | 541/3782 |
| Any Respiratory, thoracic and mediastinal disordersRespiratory, thoracic and mediastinal disorders | 538/3772 | 510/3782 |
| Any Vascular disordersVascular disorders | 440/3772 | 414/3782 |
| Any Injury, poisoning and procedural complicationsInjury, poisoning and procedural complications | 433/3772 | 353/3782 |
| Any Skin and subcutaneous tissue disordersSkin and subcutaneous tissue disorders | 337/3772 | 289/3782 |
| Any Cardiac disordersCardiac disorders | 301/3772 | 314/3782 |
| Age, Customized(participants) | Clopidogrel + ASA | Placebo + ASA | Total |
|---|---|---|---|
| 18 to <65 years | 931 | 935 | 1866 |
| 65 to <75 years | 1291 | 1258 | 2549 |
| >= 75 years | 1550 | 1589 | 3139 |
| Age, Continuous(years) | Clopidogrel + ASA | Placebo + ASA | Total |
|---|---|---|---|
| Mean | 70.9 ± 10.2 | 71.1 ± 10.2 | 71.0 ± 10.2 |
| Sex: Female, Male(Participants) | Clopidogrel + ASA | Placebo + ASA | Total |
|---|---|---|---|
| Female | 1560 | 1597 | 3157 |
| Male | 2212 | 2185 | 4397 |
| CHADS2 Score(participants) | Clopidogrel + ASA | Placebo + ASA | Total |
|---|---|---|---|
| 0 | 105 | 101 | 206 |
| 1 | 1360 | 1338 | 2698 |
| 2 | 1263 | 1315 | 2578 |
| >2 | 1040 | 1028 | 2068 |
| Missing | 4 | 0 | 4 |
| Sitting Systolic Blood Pressure(participants) | Clopidogrel + ASA | Placebo + ASA | Total |
|---|---|---|---|
| <120 mmHg | 603 | 620 | 1223 |
| >=120 mmHg | 3166 | 3159 | 6325 |
| Missing | 3 | 3 | 6 |
| Body Mass Index (BMI)(kg/m²) | Clopidogrel + ASA | Placebo + ASA | Total |
|---|---|---|---|
| Mean | 28.370 ± 5.575 | 28.459 ± 6.022 | 28.415 ± 5.803 |
The record gives a start of Jun 2003, a primary completion of Mar 2009 and a completion of Mar 2009. It does not say whether these dates are actual or estimated.
Results were first posted in Mar 2010, 1 year after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in May 2015. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Clopidogrel